Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA and KEYTRUDA QLEX Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+

Merck & Co. (MRK) Announces FDA Approval of KEYTRUDA and KEYTRUDA QLEX Plus Paclitaxel, With or Without Bevacizumab, to Treat Adults With PD-L1+ — alphai